You are here

patents

Amarin vs. the Generics: Who Will Win?

Amarin vs. the Generics: Who Will Win?

Motley Fool

Flag link:

Major generic makers will partner with Medicines Patent Pool to pursue voluntary licenses for Covid-19 drugs

Major generic makers will partner with Medicines Patent Pool to pursue voluntary licenses for Covid-19 drugs

Stat

Flag link:

Testing requirements are likely slowing biosimilar entries in the US

Testing requirements are likely slowing biosimilar entries in the US

RAPS.org

Flag link:

Covid-19 Vaccine Frontrunner Moderna Won’t Enforce Vaccine Patents During Pandemic

Covid-19 Vaccine Frontrunner Moderna Won’t Enforce Vaccine Patents During Pandemic

Forbes

Moderna Therapeutics

Flag link:

Teva back on the hook for $235M to GSK for heart drug infringement

Teva back on the hook for $235M to GSK for heart drug infringement

Fierce Pharma

Patent Infringement

Flag link:

Medtronic Takes the Gloves Off in Patent War with Axonics

Medtronic Takes the Gloves Off in Patent War with Axonics

Medical Devices and Diagnostics Industry

sacral neuromodulation

Flag link:

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Endpoints

Flag link:

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Yahoo/Bloomberg

Flag link:

AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman

AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman

Fierce Pharma

Flag link:

Moderna failed to disclose federal funding for vaccine patent applications, advocates say

Moderna failed to disclose federal funding for vaccine patent applications, advocates say

Stat

Moderna Therapeutics

Department of Defense

Flag link:

U.S. court upholds patent for Novartis MS drug Gilenya

U.S. court upholds patent for Novartis MS drug Gilenya

Reuters

multiple sclerosis

Flag link:

Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug

Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Chelation Partners Announces Issuance of U.S. Patent Covering Composition of Matter for DIBI and Related Compounds for Controlling Infections

Chelation Partners Announces Issuance of U.S. Patent Covering Composition of Matter for DIBI and Related Compounds for Controlling Infections

CP Wire

Chelation Partners

antibiotic resistance

Flag link:

Chelation Partners Announces Issuance of U.S. Patent Covering Composition of Matter for DIBI and Related Compounds for Controlling Infections

Chelation Partners

antibiotic resistance

Flag link:

Moderna's Vaccine Technology Continues to be Tangled in Patent Challenges

Moderna's Vaccine Technology Continues to be Tangled in Patent Challenges

BioSpace

Moderna Therapeutics

Arbutus BioPharma

Flag link:

Moderna's stock falls the day after 'disappointing' patent ruling

Moderna's stock falls the day after 'disappointing' patent ruling

Marketwatch

Moderna Therapeutics

Arbutus BioPharma

Flag link:

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report

Fierce Pharma

Flag link:

AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

BioPharma Dive

Flag link:

Amgen's Enbrel Patents to Be Upheld Through 2029

Amgen's Enbrel Patents to Be Upheld Through 2029

Motley Fool

rheumatoid arthritis

Flag link:

Mylan, seeking to market Victoza generic, convinces panel to start up patent review

Mylan, seeking to market Victoza generic, convinces panel to start up patent review

Fierce Pharma

Flag link:

Pages